RxDoctor Payments Data

Michelle Houghton

Psychiatric/Mental Health · Fort Madison, IANPI 1609445733

Payments from drug & device makers

$1,706in general payments, 2019–2025

Across 31 payments — averaging $55.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$433
  • AbbVie$383
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$293
  • E.r. Squibb & Sons, L.L.C.$217
  • Alkermes, Inc.$193
  • Otsuka America Pharmaceutical, Inc.$188

What the payments were for

  • Food & beverage$1,65897%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,706 in reported general payments places this provider in the 65th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$35,954
Medicare patients
106
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$178,126
RexultiBrexpiprazole49$71,218
Abilify AsimtufiiAripiprazole12$67,908
TrintellixVortioxetine Hydrobromide28$20,119
Lurasidone Hcl50$15,909
FetzimaLevomilnacipran Hcl14$13,396
Aripiprazole268$6,642
Paliperidone ErPaliperidone20$6,445
EdluarZolpidem Tartrate11$5,805
Mirtazapine157$2,769
Divalproex Sodium36$2,752
Quetiapine Fumarate200$2,701
Clonazepam304$2,686
Olanzapine78$2,522
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine83$2,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii$188$139,12661 claims
AbbVieFetzima$383$13,39614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Fort Madison

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →